Kaper, T., Lager, I., Looger, L
This could explain why tirzepatide (which stimulates the GIP pathway in addition to GLP -1) can be administered at higher doses than semaglutide (which only stimulates GLP-1), without amplifying the side effects typical of GLP-1 agonists (nausea, vomiting)
Patients have a right to be educated and informed about the possible side effects and risks associated with Wegovy, Ozempic or any other prescription drug
This highlights the possibility that GLP-1 could activate VANs that innervate either the gut or the hepatoportal region to signal to the brain and back down to the pancreas via vagovagal reflexes to induce insulin secretion 124
Why: Less effective than IV or IM as less effective due to slower absorption and less direct absorption
The votes are advisory and non-binding